Humatrix, a novel myoepithelial matrical gel with unique biochemical and biological properties.
Myoepithelial cells in situ and in vitro exert important paracrine effects on carcinoma cells which are mediated by high expression of extracellular matrix molecules, proteinase inhibitors and angiogenic inhibitors. Myoepithelial xenografts (human matrix secreting (HMS)-X, HMS-3X and HMS-4X) established from benign human salivary gland and breast myoepithelial tumors accumulate an abundant extracellular matrix which can be extracted with 6 M urea and 2 M guanidinium hydrochloride to form a gel at 25-37 degrees C. This gel, termed Humatrix, exhibits different biochemical and biological properties than the conventional non-human matrical gels in existence, i.e. Matrigel and Vitrogen 100. Whereas Matrigel consists mainly of basement membrane molecules, e.g. laminin, type IV collagen and heparan sulfate proteoglycan, and Vitrogen 100 consists mainly of non-basement membrane molecules, e.g. type I and type III collagen, Humatrix contains significant amounts of both basement membrane and non-basement membrane molecules, including large amounts of chondroitin sulfate proteoglycan. Like Matrigel, Humatrix contains bound growth factors, including epidermal growth factor (EGF) and insulin-like growth factor-I (IGF-I); unlike Matrigel, which contains predominantly significant quantities of bound proteinases, including tissue-type plasminogen activator (tPA), matrix metalloproteinase (MMP)-2 and MMP-9, and angiogenic factors, including basic fibroblast growth factor (bFGF) and transforming growth factor (TGF)-beta, Humatrix contains predominantly bound proteinase inhibitors such as protease nexin II (PN-II) and alpha1-antitrypsin and angiogenic inhibitors such as thrombospondin-1. Humatrix selectively stimulates the growth and tumorigenicity of human myoepithelial cell lines but inhibits invasion, angiogenesis and metastasis of other non-myoepithelial malignant cell lines. Because of its myoepithelial origin Humatrix represents a more natural source of extracellular matrix molecules and bound factors that carcinoma cells encounter in vivo.
Kedeshian
P
P
Department of Pathology, UCLA School of Medicine, Los Angeles, CA 90024, USA.
Sternlicht
M D
MD
Nguyen
M
M
Shao
Z M
ZM
Barsky
S H
SH
D000818:Animals; D015153:Blotting, Western; D003094:Collagen / Q000737:chemistry / Q000502:physiology; D004338:Drug Combinations; D004815:Epidermal Growth Factor / Q000737:chemistry* / Q000502:physiology*; D005109:Extracellular Matrix / Q000737:chemistry / Q000378:metabolism / Q000502:physiology*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000737:chemistry* / Q000502:physiology*; D007797:Laminin / Q000737:chemistry / Q000502:physiology; D051379:Mice; D008810:Mice, Inbred C57BL; D009208:Myoepithelioma / Q000378:metabolism* / Q000473:pathology; D009361:Neoplasm Invasiveness; D009389:Neovascularization, Pathologic; D011509:Proteoglycans / Q000737:chemistry / Q000502:physiology; D011817:Rabbits; D012513:Sarcoma, Experimental / Q000378:metabolism / Q000473:pathology; D014183:Transplantation, Heterologous; D014407:Tumor Cells, Cultured
D004338:Drug Combinations; C110897:Humatrix; D007797:Laminin; D011509:Proteoglycans; C093679:Vitrogen; C059485:matrigel; D004815:Epidermal Growth Factor; D007334:Insulin-Like Growth Factor I; D003094:Collagen